Chen Jian-Guo, Chen Hai-Zhen, Zhu Jian, Shen Ai-Guo, Sun Xiang-Yang, Parkin Donald Maxwell
Department of Epidemiology, Nantong Tumor Hospital, Affiliated Tumor Hospital of Nantong University, Nantong, China.
Department of Epidemiology, Qidong Liver Cancer Institute, Qidong People's Hospital, Affiliated Qidong Hospital of Nantong University, Qidong, China.
Front Oncol. 2023 Jun 7;13:1173828. doi: 10.3389/fonc.2023.1173828. eCollection 2023.
Cancer survival is an important indicator for evaluating cancer prognosis and cancer care outcomes. The incidence dates used in calculating survival differ between population-based registries and hospital-based registries. Studies examining the effects of the left truncation of incidence dates and delayed reporting on survival estimates are scarce in real-world applications.
Cancer cases hospitalized at Nantong Tumor Hospital during the years 2002-2017 were traced with their records registered in the Qidong Cancer Registry. Survival was calculated using the life table method for cancer patients with the first visit dates recorded in the hospital-based cancer registry (HBR) as the diagnosis date (), those with the registered dates of population-based cancer (PBR) registered as the incidence date (), and those with corrected dates when the delayed report dates were calibrated ().
Among 2,636 cases, 1,307 had incidence dates registered in PBR prior to the diagnosis dates of the first hospitalization registered in HBR, while 667 cases with incidence dates registered in PBR were later than the diagnosis dates registered in HBR. The 5-year , , and were 36.1%, 37.4%, and 39.0%, respectively. The "lost" proportion of 5-year survival due to the left truncation for HBR data was estimated to be between 3.5% and 7.4%, and the "delayed-report" proportion of 5-year survival for PBR data was found to be 4.1%.
Left truncation of survival in HBR cases was demonstrated. The pseudo-left truncation in PBR should be reduced by controlling delayed reporting and maximizing completeness. Our study provides practical references and suggestions for evaluating the survival of cancer patients with HBR and PBR.
癌症生存率是评估癌症预后和癌症护理效果的重要指标。基于人群的登记处和基于医院的登记处在计算生存率时所使用的发病日期有所不同。在实际应用中，研究发病日期左截断和延迟报告对生存估计影响的研究较少。
对2002年至2017年在南通肿瘤医院住院的癌症病例进行追踪，其记录登记在启东癌症登记处。使用生命表法计算癌症患者的生存率，将在基于医院的癌症登记处（HBR）记录的首次就诊日期作为诊断日期（），将基于人群的癌症登记处（PBR）登记的日期作为发病日期（），以及在校准延迟报告日期后的校正日期（）。
在2636例病例中，1307例的发病日期在HBR登记的首次住院诊断日期之前登记在PBR中，而667例发病日期在PBR登记的病例晚于在HBR登记的诊断日期。5年、和分别为36.1%、37.4%和39.0%。HBR数据因左截断导致的5年生存率“损失”比例估计在3.5%至7.4%之间，PBR数据的5年生存率“延迟报告”比例为4.1%。
证实了HBR病例生存的左截断情况。应通过控制延迟报告和最大化完整性来减少PBR中的假左截断。我们的研究为评估HBR和PBR癌症患者的生存情况提供了实际参考和建议。
Zotero 插件
